4'-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms

Neuropharmacology. 2024 Jun 15:251:109926. doi: 10.1016/j.neuropharm.2024.109926. Epub 2024 Mar 28.


We tested the efficacy of 4'-fluorocannabidiol (4'-F-CBD), a semisynthetic cannabidiol derivative, and HU-910, a cannabinoid receptor 2 (CB2) agonist in resolving l-DOPA-induced dyskinesia (LID). Specifically, we were interested in studying whether these compounds could restrain striatal inflammatory responses and rescue glutamatergic disturbances characteristic of the dyskinetic state. C57BL/6 mice were rendered hemiparkinsonian by unilateral striatal lesioning with 6-OHDA. Abnormal involuntary movements were then induced by repeated i.p. injections of l-DOPA + benserazide. After LID was installed, the effects of a 3-day treatment with 4'-F-CBD or HU-910 in combination or not with the TRPV1 antagonist capsazepine (CPZ) or CB2 agonists HU-308 and JWH015 were assessed. Immunostaining was conducted to investigate the impacts of 4'-F-CBD and HU-910 (with CPZ) on inflammation and glutamatergic synapses. Our results showed that the combination of 4'-F-CBD + CPZ, but not when administered alone, decreased LID. Neither HU-910 alone nor HU-910+CPZ were effective. The CB2 agonists HU-308 and JWH015 were also ineffective in decreasing LID. Both combination treatments efficiently reduced microglial and astrocyte activation in the dorsal striatum of dyskinetic mice. However, only 4'-F-CBD + CPZ normalized the density of glutamate vesicular transporter-1 (vGluT1) puncta colocalized with the postsynaptic density marker PSD95. These findings suggest that 4'-F-CBD + CPZ normalizes dysregulated cortico-striatal glutamatergic inputs, which could be involved in their anti-dyskinetic effects. Although it is not possible to rule out the involvement of anti-inflammatory mechanisms, the decrease in striatal neuroinflammation markers by 4'-F-CBD and HU-910 without an associated reduction in LID indicates that they are insufficient per se to prevent LID manifestations.

Keywords: CB1; CB2; Glutamate; HU-910; Neuroinflammation; Parkinson's disease.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Antiparkinson Agents / pharmacology
  • Bridged Bicyclo Compounds*
  • Cannabidiol / analogs & derivatives*
  • Cannabinoids*
  • Capsaicin / analogs & derivatives*
  • Corpus Striatum
  • Disease Models, Animal
  • Dyskinesia, Drug-Induced* / drug therapy
  • Levodopa* / therapeutic use
  • Mice
  • Mice, Inbred C57BL
  • Oxidopamine / pharmacology
  • Rats
  • Rats, Sprague-Dawley


  • Levodopa
  • HU 308
  • HU-910
  • Antiparkinson Agents
  • HUF-101
  • capsazepine
  • Oxidopamine
  • Anti-Inflammatory Agents
  • Bridged Bicyclo Compounds
  • Cannabidiol
  • Cannabinoids
  • Capsaicin